Latest Contracts News

Heartland Group Holdings Limited reports a robust turnaround in first-half 2026 net profit, driven by margin expansion, asset quality improvements, and strong Reverse Mortgage growth in New Zealand and Australia. The group also advances significant technology investments and benefits from eased Reserve Bank capital requirements.

ZMM has reported a remarkable 253% increase in revenue for the half-year ending December 2025, yet still recorded a net loss of $1.078 million amid concerns over its financial sustainability.

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

Sprintex Limited reported a 162% surge in revenue to A$2.7 million for the half-year ending December 2025, driven by a landmark €15.6 million European contract. Despite this, the company posted a net loss of A$1.7 million, an improvement from the prior year, while raising $3.6 million to support global expansion.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Mayfield Group Holdings has announced the acquisition of SMEC Power & Technology for up to $30 million, marking its entry into underground mining electrical infrastructure and international markets.

NEXTDC has reported a robust first half of FY26, with strong revenue and earnings growth underpinned by a surging forward order book and expanded capital expenditure plans.

DUG Technology’s US subsidiary has been ordered to pay over US$2 million following a breach of contract ruling, but the company is gearing up to contest the judgment through appeals.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

Star Combo Pharma reported a 23% decline in revenue to $11.9 million for the half year ended December 2025, driven by the loss of a major OEM contract and closure of its AustoYou retail business. Despite this, operating profit after tax rose 49% to $413,243, reflecting effective cost management.

SciDev Limited posted a $2.14 million loss for the half-year ending December 2025, impacted by restructuring costs and a failed acquisition. Despite a 4% revenue dip, the company secured a major $19.5 million contract and maintains a strong balance sheet.

Appen Limited has reported a slight revenue decline and a notable increase in net loss for the 2025 financial year, prompting the company to withhold its final dividend.